本页面由Tiger Trade Technology Pte. Ltd.提供服务

Edgewise Therapeutics, Inc.

30.05
+0.36001.21%
盘前29.88-0.1700-0.57%06:27 EDT
成交量:65.94万
成交额:1,978.03万
市值:32.23亿
市盈率:-18.43
高:30.34
开:29.69
低:29.40
收:29.69
52周最高:31.82
52周最低:10.60
股本:1.07亿
流通股本:6,084.98万
量比:0.82
换手率:1.08%
股息:- -
股息率:- -
每股收益(TTM):-1.6302
每股收益(LYR):-1.6302
净资产收益率:-34.19%
总资产收益率:-23.02%
市净率:6.17
市盈率(LYR):-18.43

数据加载中...

公司资料

公司名字:
Edgewise Therapeutics, Inc.
交易所:
NASDAQ
成立时间:
2017
员工人数:
146
公司地址:
1715 38th Street,Boulder,Colorado,United States
邮编:
80301
电话:
传真:
- -
简介:
Edgewise Therapeutics, Inc.于2017年5月在特拉华州注册成立。该公司是一家以科学为驱动的生物技术公司,专注于开发针对严重肌肉疾病的疗法,最初目标是罕见神经肌肉和心脏疾病。其主要候选药物sevasemten是一种口服小分子抑制剂,正处于治疗杜氏肌营养不良和贝克尔肌营养不良的后期临床开发阶段。

董事

名称
职位
Kevin Koch
President, Chief Executive Officer and Director
Alan Russell
Chief Scientific Officer and Director
Peter Thompson
Director and Chairperson
Arlene M. Morris
Director
Badreddin Edris
Director
Christopher Martin
Director
Jonathan Fox
Director
Jonathan Root
Director
Laura Brege
Director

股东

名称
职位
Kevin Koch
President, Chief Executive Officer and Director
Robert Blaustein
Chief Operating Officer
Michael Nofi
Chief Financial Officer
Alan Russell
Chief Scientific Officer and Director
Behrad Derakhshan
Chief Business Officer
Joanne M. Donovan
Chief Medical Officer
John Moore
General Counsel